arrow Log In to View Account     |      
HOME
Johns Hopkins Medicine
Hopkins Logo


 
OPTIMAL MANAGEMENT OF NEOVASCULAR AMD: WHEN TO TREAT? WHAT TO TREAT? HOW TO TREAT?

Presented by the Johns Hopkins University School of Medicine.

This educational activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc.

GOAL

The goal of this activity is to provide retina specialists with the most current clinical knowledge and therapeutic strategies for the optimal treatment and management of patients with age-related macular degeneration.

INTENDED AUDIENCE

This activity is designed for retina specialists. No prerequisites required.

LEARNING OBJECTIVES

After completing this activity, the participant should be able to:

  • Compare the effect of dosing strategies on the efficacy and safety of current and emerging therapies for the management of AMD.
  • Evaluate how results from the latest clinical trials can be applied to clinical case scenarios and situations in actual clinical practices.
  • Assess the role of advanced imaging modalities in diagnosing and treating patients with AMD.

The Johns Hopkins University School of Medicine takes responsibility for the content, quality, and scientific integrity of this CME activity.

ACCREDITATION STATEMENT

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 2 AMA PRA Category I Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The estimated time to complete this educational activity: 2 hours.

Release date: November 1, 2013. Expiration date: November 1, 2015.

PARTICIPATING FACULTY
Howard S. Ying, MD, PhD (Co-Course Director)
Assistant Professor of Ophthalmology
Retina Division
The Wilmer Eye Institute
Johns Hopkins University School of Medicine
Baltimore, Maryland

Quan Dong Nguyen, MD, MS (Co-Course Director)
McGaw Memorial Endowed Chair in Ophthalmology
Professor and Chairman
Director of the Stanley M. Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, Nebraska

Victor Chong, MD
Head of Department
Oxford Eye Hospital
Oxford University Hospitals
Oxford, Great Britain

Diana V. Do, MD
Associate Professor of Ophthalmology
Vice Chair for Education
Director of the Carl Camras Center for Innovative
Clinical Trials in Ophthalmology
Stanley M. Truhlsen Eye Institute
University of Nebraska Medical Center
Omaha, Nebraska
HOW TO CLAIM CREDIT

Please complete a brief pre-assessment before continuing with the monograph. After reading this monograph, participants may receive credit by completing the CME test and evaluation online, and receiving a score of 70% or higher.

Faculty
Full Disclosure Policy Affecting CME Activities:
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of the Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) to require signed disclosure of the existence of financial relationships with industry from any individual in a position to control the content of a CME activity sponsored by OCME. Members of the Planning Committee are required to disclose all relationships regardless of their relevance to the content of the activity. Faculty are required to disclose only those relationships that are relevant to their specific presentation. The following relationships have been reported for this activity:

Participating Faculty Disclosures
Dr Nguyen reports receiving grants/research support from Genentech, Inc, Pfizer Inc, and Regeneron Pharmaceuticals, Inc; and for serving as a consultant/advisor for Bausch & Lomb Incorporated, Genentech, Inc, Regeneron Pharmaceuticals, Inc, and Santen Pharmaceutical Co, Ltd.

Dr Chong reports receiving grants/research support from Novartis Corporation; and for serving as a consultant for Bayer and Novartis Corporation.

Dr Do reports receiving grants/research support from Genentech, Inc and Regeneron Pharmaceuticals, Inc.

Planner Disclosures
Planning Committee: Howard S. Ying, MD, PhD; Quan Dong Nguyen, MD; Jessica N. Falco, PhD.

Dr Ying reports serving as a co-principal investigator for Novartis AG and Regeneron Pharmaceuticals, Inc.

Dr Nguyen reports serving as a principal investigator for Abbott Laboratories, Genentech, Inc, Lux Biosciences, Inc, Regeneron, Inc, and Santen Pharmaceutical Co Ltd; and serving as a consultant for Bausch & Lomb Incorporated and Santen Pharmaceutical Co, Ltd.

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grant, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

Off-Label Product Discussion
The following faculty members have disclosed that their presentation will reference unlabeled/unapproved use of drugs or products:

Dr Ying—bevacizumab and triamcinolone.
Dr Nguyen—bevacizumab and ranibizumab.
Dr Chong—bevacizumab and ranibizumab.
Dr Do—bevacizumab and ranibizumab.

DISCLAIMER

The opinions and recommendations expressed by faculty and other experts whose input is included in this program are their own. This enduring material is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format design and approach. Please review the complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

INTERNET CME POLICY

The Office of Continuing Medical Education (CME) at the Johns Hopkins University School of Medicine is committed to protect the privacy of its members and customers. Johns Hopkins University SOM CME maintains its Internet site as an information resource and service for physicians, other health professionals, and the public. Continuing Medical Education at the Johns Hopkins University School of Medicine will keep your personal and credit information confidential when you participate in a CME Internet based activity. Your information will never be given to anyone outside of the Johns Hopkins University School of Medicine’s CME activity. CME collects only the information necessary to provide you with the services that you request.

Confidentiality Disclaimer for CME Activity Participant

I certify that I am participating in a Johns Hopkins University School of Medicine CME activity for accredited training and/or educational purposes.

I understand that while I am attending in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the "Privacy Regulations"). Protected health information is information about a person's health or treatment that identifies the person. I also understand that while I am participating in this capacity I will be treated as a temporary member of Johns Hopkins for purposes of the Privacy Regulations only.

I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential.

I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.

“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as provider of this activity, has relayed information with the CME attendees/participants and certifies that the visitor is attending for training, education and/or observation purposes only.”

For CME Questions, please contact the CME Office (410) 955-2959 or e-mail cmenet@jhmi.edu.

Johns Hopkins University School of Medicine
Office of Continuing Medical Education
Turner 20/720 Rutland Avenue
Baltimore, Maryland 21205-2195
Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (Updated 4/09)

HARDWARE & SOFTWARE REQUIREMENTS

Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

ACTIVITY

Instructions
The following activity consists of 3 sections: an unaccredited pre-test, a monograph, and a CME post-test and evaluation. All 3 sections must be completed to receive CME credit.


Pre-Test

OVERVIEW
Optimal Management of Neovascular AMD:
When To Treat? What To Treat? How To Treat?


PROCEEDINGS
Updates on the Assessment and Management of Neovascular AMD
Quan Dong Nguyen, MD, MS, Diana V. Do, MD, and Victor Chong, MD

Advances in Imaging Modalities for AMD: FA, ICG, Microperimetry, OCT, and Beyond
Victor Chong, MD

Advanced Retina Workshop: Case Discussions
Howard S. Ying, MD, PhD

Post-Test
procced to pretest
footer